The recruitment process to find a successor has begun and the company’s COO Jan Nilsson will head up the company in the role of interim CEO in the period until a new CEO is appointed by the Board of Directors.
“We would like to thank Mikael Brönnegård for his service to the company and wish him success in his future endeavors. We believe that the time is right for a change in the leadership of the company’s management team. The NeuroVive board is confident that Jan Nilsson has the experience required to lead the company until a new CEO has been recruited,” commented Gregory Batcheller, NeuroVive’s Chairman.
About NeuroVive
NeuroVive Pharmaceutical AB (publ) is a mitochondrial medicine company committed to the discovery and development of therapeutic applications for mitochondrial medicine in areas of significant unmet clinical need. NeuroVive’s business strategy focuses on maximising value from its projects through strategic partnerships and outlicensing.
NeuroVive’s portfolio, containing three cyclophilin D candidates in clinical and preclinical development, is fuelled by three additional drug discovery platforms in neurology, mitochondrial disorders and organ protection. NeuroVive’s product CicloMulsion® is being evaluated in an ongoing Phase II study, CiPRICS, in acute kidney injury during major surgery. The NeuroSTAT® product is currently being evaluated in a Phase II study in traumatic brain injury. NeuroVive’s shares are listed on NASDAQ OMX, Stockholm, Sweden.
For investor relations and media questions, please contact:
Ingmar Rentzhog, Laika Consulting, Tel: +46 (46)275 62 21 or ir@neurovive.se
It is also possible to arrange an interview with NeuroVive’s Chairman Gregory Batcheller at the above contacts.
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48
info@neurovive.se, www.neurovive.se
NeuroVive Pharmaceutical AB (publ) is required to publish the information in this news release under The Swedish Securities Market Act. The information was submitted for publication on 1 September 2015, at 13.50 CET.